Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,792 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
Miami, FloridaAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT06508463RecruitingPhase 1
Viral therapy for peripheral T-cell lymphoma
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Scottsdale, ArizonaAges 18 years+ - NCT06376162RecruitingPhase 1
Ziftomenib with chemo for kids with relapsed acute leukemia
This trial tests a new targeted drug called ziftomenib combined with chemotherapy for children whose leukemia (with specific genetic changes) has come back or is not responding to treatment. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges birth–21 years - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT06523556RecruitingPhase 1/Phase 2
Study of axatilimab with or without azacitidine for advanced blood cancers
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
Columbus, OhioAges 18 years+ - NCT05549661RecruitingPhase 1
Onvansertib for hard-to-treat CMML and MDS/MPN
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Rochester, MinnesotaAges 18 years+ - NCT07690761Enrolling by invitationPhase 2
Rituximab and Zanubrutinib for hairy cell leukemia
This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.
HaifaAges 18 years+ - NCT02390635RecruitingPhase 1
Testing PET/MRI scans to find leukemia outside the bone marrow
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
Houston, TexasAges 18 years+ - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Birmingham, AlabamaAges 1–25 - NCT07270770RecruitingPhase 1
A New Drug BY002 for Relapsed Acute Leukemia with Genetic Changes
This phase 1 trial tests a new drug called BY002 for people with certain types of leukemia (AML, ALL, or MPAL) that have come back or not responded to treatment. It focuses on patients whose leukemia has a specific genetic change (KMT2A rearrangement or NPM1 mutation). The goal is to see if BY002 can help control the disease.
Suzhou, JiangsuAges 16 years+ - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT04905810RecruitingPhase 2
Azacitidine or decitabine plus venetoclax for AML after prior failure
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Clovis, CaliforniaAges 18 years+ - NCT04941716RecruitingPhase 2
Acalabrutinib plus venetoclax for hard-to-treat CLL/SLL
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
Seattle, WashingtonAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Newport Beach, CaliforniaAges 12 years+ - NCT05792007Recruiting
Study of bone marrow environment in childhood leukemia
This study looks at what the bone marrow “microenvironment” is like in children newly diagnosed with acute leukemia, to better understand the disease. It also compares leukemia samples to samples from children having certain orthopedic surgery.
ToursAges 1–15 - NCT06698484RecruitingPhase 2
CAR-T cell therapy for B-cell lymphoma that has returned or not responded
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Bandar Tun Razak, Kuala LumpurAges 13–75 - NCT06721689RecruitingPhase 1/Phase 2
PEEL-224 with chemo for pediatric solid tumors
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Los Angeles, CaliforniaAges 1–30 - NCT00412594RecruitingPhase 2
Cladribine plus rituximab for hairy cell leukemia
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
Houston, TexasAges 18 years+ - NCT04239157RecruitingPhase 2
Canakinumab shot for lower-risk MDS and related blood disorders
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
Houston, TexasAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,792 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.